Silica Nanoparticles With Encapsulated DNA (SPED) to Trace the Spread of Pathogens in Healthcare

Cinzia Ullrich

University of Zurich Faculty of Medicine: Universitat Zurich Medizinische Fakultat

Anne M Luescher

ETH Zurich Department of Chemistry and Applied Biosciences: Eidgenossische Technische Hochschule
Zurich Departement Chemie und Angewandte Biowissenschaften

Julian Koch

ETH Zurich Department of Chemistry and Applied Biosciences: Eidgenossische Technische Hochschule
Zurich Departement Chemie und Angewandte Biowissenschaften

Robert N Grass

ETH-Zurich, Dept Chemistry and Applied Biosciences

Hugo Sax (✉ hugo.sax@mac.com)

Bern University Hospital <https://orcid.org/0000-0002-1532-2198>

Research

Keywords: Infection control, infection prevention, pathogen transmission, silica nanoparticles, surrogate markers

Posted Date: September 14th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-870804/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Antimicrobial Resistance and Infection Control on January 10th, 2022. See the published version at <https://doi.org/10.1186/s13756-021-01041-3>.

Silica nanoparticles with encapsulated DNA (SPED) to trace the spread of pathogens in healthcare

Authors: Cinzia Ullrich (1)*, Anne M. Luescher (2)*, Julian Koch (2), Robert N. Grass (2)†, Hugo Sax (1,3)†

* These authors contributed equally to this article as first authors.

† These authors contributed equally to this article as last authors.

(1) Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

(2) Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland

(3) Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland

Correspondence to:

Prof Hugo Sax, MD, Giessereistrasse 12, 8005 Zurich, Switzerland; email: hugo.sax@mac.com; phone: +41-79-309-3888

Prof. Dr. Robert Grass, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland; email: robert.grass@chem.ethz.ch; phone: +41-44-633-6334

Keywords: Infection control, infection prevention, pathogen transmission, silica nanoparticles, surrogate markers

Abstract (Word count: 350/350)

Background: To establish effective infection control protocols, understanding pathogen transmission pathways is essential. Non-infectious surrogate tracers may safely explore these pathways and challenge pre-existing assumptions. We used silica nanoparticles with encapsulated DNA (SPED) for the first time in a real-life hospital setting to investigate potential transmission routes of vancomycin-resistant enterococci in the context of a prolonged outbreak.

Methods: The two study experiments took place in the 900-bed University Hospital Zurich, Switzerland. A three-run ‘Patient experiment’ investigated pathogen transmission via toilet seats in a two-patient room with shared bathroom. First, various predetermined body and fomite sites in a two-bed patient room were probed at baseline. Then, after the first patient was contaminated with SPED at the subgluteal region, both patients sequentially performed a toilet routine. All sites were consequently swabbed again for SPED contamination. Eight hours later, further spread was tested at predefined sites in the patient room and throughout the ward. A two-run ‘Mobile device experiment’ explored the potential transmission by mobile phones and stethoscopes in a quasi-realistic setting. All SPED contamination statuses and levels were determined by real-time qPCR.

Results: Over all three runs, the ‘Patient experiment’ yielded SPED in 59 of 73 (80.8 %) predefined body and environmental sites. Specifically, positivity rates were 100 % on subgluteal skin, toilet seats, tap handles, and entertainment devices, the initially contaminated patients’ hands; 83.3 % on patient phones and bed controls; 80 % on intravenous pumps; 75 % on toilet flush plates and door handles, and 0 % on the initially not contaminated patients’ hands. SPED spread as far as doctor’s keyboards (66.6 %), staff mobile phones (33.3 %) and nurses’ keyboards (33.3 %) after eight hours. The ‘Mobile device experiment’ resulted in 16 of 22 (72.7 %) positive follow-up samples, and transmission to the second patient occurred in one of the two runs.

52 **Conclusions:** For the first time SPED were used to investigate potential transmission
53 pathways in a real hospital setting. The results suggest that, in the absence of targeted
54 cleaning, toilet seats and mobile devices may result in widespread transmission of pathogens
55 departing from one contaminated patient skin region.
56

Background

Healthcare associated infections (HCAI) cause higher complication and mortality rates, prolonged hospital stays, and increased healthcare costs (1, 2). Moreover, the spread of antimicrobial resistant pathogens is considered one of the most crucial issues in healthcare (3).

Multiple large-scale outbreaks of vancomycin-resistant enterococci (VRE) in Swiss hospitals in the last decade indicate a surge of VRE in Switzerland (4-6). Poor hand hygiene (HH) has proven to be a primary cause of pathogen transmission (7). Guidelines and protocols have been established to improve hand hygiene in healthcare (2, 8) with limited overall success (9, 10). Several studies published over the past 20 years indicate the effect of contaminated hospital environment on pathogen transmission – especially multi-resistant pathogens such as VRE (11-14). Pittet et al. (7) list “*organisms shed onto inanimate objects immediately surrounding the patient*” as the starting point of cross-transmission between patients. Other studies suggest that the risk for VRE acquisition is higher when a patient stays in a hospital room previously occupied by a VRE-infected patient (15-17). Lower rates of multi-drug resistant pathogen colonization and infection occur in hospitals with single-rooms and thus, individualized toilet use (18, 19).

Touching a VRE-contaminated surface carries a similar risk for pathogen-transmission on hands as touching a colonized patient even though the concentration of VRE on surfaces is much lower (12, 20, 21). Randle et al. (22) found that HH compliance in HCW was 80% (adjusted odds ratio (aOR) 1.88, 95% CI 1.15–3.07) after direct patient contact, whereas HH was performed in only 50% (aOR 0.60, 95% CI 0.38–0.93) after contact with a patient’s surroundings. In an observational study with head cameras during real-life active patient care Clack et al. even found a HH “adherence” of only 5% prior to potentially patient colonizing touch events and only 1% before possible infection events (e.g., before touching central line insertion sites, wounds, sterile needles) (10).

It is not surprising that Cassone et al. (23) included toilet seats in an environmental panel as a proxy for patients with VRE colonization. Although many experts emphasize the transmission of pathogens from contaminated areas through the hands of healthcare workers (HCW), fewer recognize the effect of shared bathrooms or toilets as possible transmission hubs of multi-drug resistant microorganisms (24). The transmission pathway of pathogens, in particular VRE, through toilet seats has not yet been explicitly investigated.

The use of surrogate tracers allows to safely determine patient-to-patient-transmission of pathogens in real-life care-settings (25, 26). In the past, various pathogen surrogates have been used, including cauliflower mosaic virus DNA (27-31), bacteriophage MS-2 (29, 32, 33), non-toxicogenic *Clostridioides difficile* spores (34), fluorescent agents (35), and light-reflecting chemical compounds combined with flashlight photography (33). Silica nanoparticles with encapsulated DNA (SPED) with known nucleotide sequences have been described by Paunescu et al. (36) (**Annex Figure 1**). They are used as inert tracers in biological product tagging, tracing of food, studying animal predator-prey-relationships, and characterizing aquifer and wastewater (37-40). As Scotoni et al. (25) have shown in a microbiology and a behaviour laboratory setting, that SPED represent promising surrogate tracers for microbial transmission in healthcare because SPED and bacteria share strong similarities in transmission, are non-toxic, and can be individually tagged (41).

In the current work, we aimed to investigate the spread of SPED as surrogates for pathogen transmission between patients in a real-world-scenario, involving the shared use of the toilet in a two-bed patient room. This investigation was clinically motivated by an ongoing VRE outbreak in our hospital in the course of which the risk of shared restroom use and necessary cleaning schedules became a topic of interest.

Methods

SPED and swab technique

The synthesis and characterization of SPED followed the protocol of Paunescu et al. (36). We used the same three batches of SPED with individual DNA-tagging as previously described by Scotoni et al. (25), SPED-1 ($218 \pm 80\text{nm}$; DNA loading $21\mu\text{g}$), SPED-2 ($146.6 \pm 46\text{nm}$; DNA loading $23\mu\text{g}$), and SPED-3 ($173.4 \pm 82\text{nm}$; DNA loading $26\mu\text{g}$). The nature and handling of SPED is described in detail in the **Technical Appendix**.

Quantification of SPED and statistical analysis

The procurance of exact SPED concentration levels based on real-time quantitative PCR (qPCR) cycle values is specified in the **Technical Appendix**. To evaluate the corresponding concentrations in mg/mL , all samples were compared with an experiment-specific threshold resulting from the SPED concentration of the baseline sample yielding the strongest qPCR signal and thus, the highest concentration of all baseline samples. This represents a conservative approach to adjust all results for background signals resulting from (cross-)contamination arising during experimental processing. Consequently, values with concentrations above threshold were considered as positive, values below as negative. The descriptive analysis was conducted with Microsoft Excel® 2020.

Explorative experiments

Before their use with patients, we chose to explore SPED for transmission characteristics in relation to the necessary amount and concentration in the restroom of an office building of the hospital campus in two controlled experiments.

First, 3 mL of a 1 mg/mL SPED suspension in ultrapure MilliQ water (type 1, $18.2\text{M}\Omega\cdot\text{cm}$ at 24°C , Milli-Q®; Merck, Darmstadt, Germany) were deposited on bare skin at

a subgluteal skin site of a voluntary 27-year-old male participant and left to air-dry. The participant was then asked to sit on the toilet seat for ten seconds, flush the toilet, and perform handwashing after having left the restroom by using the door handle. The participant's contaminated body site, toilet seat, toilet flush plate, door handle, and tap were swabbed before and after this sequence. In a follow-up experiment, we verified the transmission of SPED from a **Participant-A**, contaminated equally as described above, to **Participant-B**, both subsequently performing the same toilet use sequence as described above.

Patient experiment

The patient experiment took place in patient rooms on a haemato-oncological ward at the University Hospital Zurich, Switzerland, it was repeated three times (**Run-1–Run-3**) with a new SPED batch being used (**SPED-1–SPED-3**) for each run. **Run-1** and **Run-2** took place in the same, **Run-3** in another patient room of similar layout (**Figure 1**). During the experiment, cleaning in the patient room was limited to floor wiping.

Any pair of patients in a two-bed room were eligible for the study if they both gave informed consent. They were conveniently chosen by ward staff and allowed to withdraw at any time without indicating a reason.

We pre-defined 20 swabbing sites dimensioned 1 x 3 cm, 16 concerning fomites, of which eight were located inside, four in the restroom and four outside the patient room, and two body sites on each patient (Table 1). These swab sites were chosen following the idea of ‘high-touch surfaces’ according to Huslage et al. (42). Swabbing was performed as described in the **Technical Appendix**.

First, all sites were swabbed as negative controls. Then, we applied 3 mL of our SPED test suspension (1 mg/mL) to the subgluteal region of **Patient-A** by using a graduated pipette and a brush and left it to air-dry. A swab from the subgluteal swabbing sites of **Patient-A** taken immediately after contamination constituted the positive control. Consecutively, we

asked **Patient-A** to dress, go to the bathroom and sit on the toilet seat for 10 s. Then **Patient-A** would dress, flush the toilet, perform handwashing with soap and water, open the bathroom door and go back to bed. Immediately after this sequence, we took swabs of **Patient-A**'s subgluteal skin as well as from the toilet seat, tap handle, flush plate, and bathroom door handle. Subsequently, **Patient-B** was asked to perform the same toilet use sequence as **Patient-A**. We again took samples from the predefined **Patient-B** and environmental swabbing sites. Then, the researcher left the ward asking both patients to behave as usual.

After an eight-hour interval, the researcher returned to the ward and sampled both patients' hands and three predefined environmental sites for each patient (i.e., bed control unit, phone, the personal entertainment device that the patient reported to have mainly used among laptop, e-reader, tablet, hospital-bedside TV, and intravenous pump). Keyboards and mobile phones of the nurse and the physician intern in charge of **Patient-A** and **Patient-B** were swabbed accordingly (**Table 1**).

Mobile device experiment

To investigate whether SPED transmit from one patient to another through HCW mobile phones, we conceived an additional quasi-realistic experiment with the help of healthy volunteers.

Four volunteers performed a standardized scenario as **Patient-A'**, **Patient-B'**, **Doctor-A**, and **Doctor-B** in a simulated two-bed hospital room involving personal stethoscopes and a single shared mobile phone (**Figure 2**), repeated as **Run-1'** and **Run-2'** using **SPED-3** and **SPED-2**, respectively. SPED were deployed on **Patient-A'**'s wrist, chest, and neck. Then, **Doctor-A** examined **Patient-A'**, answered the mobile phone, which was consequently used by **Doctor-B**, who in turn examined **Patient-B'**. Before SPED deployment and after, the experiment swabs were taken from the patients' wrists, neck and chest, both doctors' hands

and cheeks, and both stethoscopes as well as the front and back of the mobile phone
(Table 2).

Results

Explorative experiments

Both explorative experiments successfully established transmission signals with the applied SPED amount and concentration from human skin to inanimate surfaces and back to skin (Figure 3). After testing different cleaning processes, we found a thorough cleaning process using water and a household detergent (Oekoplan, Coop) eliminating SPED (Figure 3).

Patient experiment

Overall, 133 swabs were collected during **Run-1** to **Run-3**. The highest concentrations for 60 negative control samples before SPED deployment for **Run-1**, **Run-2**, and **Run-3** were 3.01×10^{-8} mg/mL (SPED 3), 9.55×10^{-9} mg/mL (SPED 2) and 8.21×10^{-9} mg/mL (SPED-1), respectively, serving as run-specific positivity thresholds. Of the remaining 73 samples, 59 (80.8 %) were positive (Figure 4). Although the recovered SPED followed the logic of reduced concentrations with multiple touching sequences, there were considerable quantitative differences between the runs. Over all three runs, positivity rates were 100 % on subgluteal skin, toilet seats, tap handles, and entertainment device controls, **Patient-A**'s hands; 83.3 % on patient phones and bed controls; 80 % on intravenous pumps; 75 % on toilet flush plate and door handle, 66.6 % on doctor's keyboards; and 33.3 %, on nurses' or doctors' phones, nurse's keyboards, and 0 % on **Patient-Bs**' hands.

199 *Mobile device experiment*

200 Overall, 56 samples were collected. Positivity thresholds in 28 baseline samples were
201 7.36×10^{-7} mg/mL (SPED-3) and 1.63×10^{-7} mg/mL (SPED-2) for **Run-1'** and **Run-2'**,
202 respectively. The baseline sample of **Doctor-A's** hands in **Run-1'** was accidentally
203 contaminated and ignored. Of the 22 post-experiment samples, not including the initial SPED
204 deposition sites on **Patient A'**, 16 (72.7 %) tested positive for SPED (**Figure 5**).

205 **Discussion**

206 After Scotoni et al. (25) explored SPED transmission in the laboratory and found their
207 behaviour to be similar to that of bacteria, the current study employed SPED for the first time
208 in a real-life hospital environment. After establishing the method of skin contamination and
209 sampling, we found SPED transmission from one patient to another via toilet use and spread
210 to patient surroundings as far as distant HCWs' mobile phones and keyboards consistently
211 over all runs. An additional off-site experiment confirmed that HCW mobile phones indeed
212 transmitted SPED between patients.

213 The patient experiment indicated SPED spreading from **Patient-A's** subgluteal skin
214 region to the toilet seat and from there to the subgluteal region of the roommate **Patient-B**. In
215 addition, **Patient-A** contaminated the toilet flush plate, tap handle, and door handle with their
216 hands with SPED which were acquired from a contaminated body part or environmental site
217 beforehand. **Patient-B** became contaminated on the subgluteal skin site by exposure to the
218 toilet seat. Of note, SPED were detected on the door handle in most of the cases, even though
219 touching of the door handle occurred after handwashing in the study scenario. This implies
220 that SPED had not been completely removed by handwashing. This contrasts the findings of
221 Scotoni et al. (25) who investigated handwashing under laboratory conditions, but it

positively simulates insufficient handwashing after toilet usage that has frequently been reported as typical population behaviour (43).

Eight hours after initial exposure, SPED have found their way to many surfaces in the immediate surroundings of the two patients and, in some instances reached the mobile phones and keyboards of the HCWs in charge of the patients, far from their room. Although SPED were always detectable on **Patient-As**' hands, swabs of **Patient-Bs**' hands were consistently negative. Nevertheless, SPED were found on all entertainment devices swabbed during the experiment, indicating a relevant but transient contamination of the patient's hands. Swabs of **Patient-A**'s bed position controls, phones, entertainment devices, and intravenous pumps were uniformly positive, as were most swabs of **Patient-Bs**' bed position controls, phones, and intravenous pumps. **Patient-B** tended to show lower SPED levels than **Patient-A**, consistent with the logic of a dilution effect over propagated spreading along a multi-touch transmission pathway (**Figure 4**). The lower SPED concentration found on flush plates could be explained by an uneven distribution of SPED over the hands and the way toilet handles were touched, as shown by Scotoni et al. before (25).

Intravenous pumps, which are typically only operated by nurses, showed a positive signal for SPED in 80 %. This echoes the findings by Huslage et al. (42), who considered these devices as "high-touch" surfaces and implied HCW hands as transmission hubs. Alternatively, but less likely, patients touched their intravenous pump themselves.

Pathogens found on toilet seats are often of faecal or skin origin including *Escherichia. coli*, sensitive Enterococci, VRE, and methicillin-resistant *Staphylococcus aureus* (MRSA) (44, 45). Toilet seats have been suspected as culprits for VRE transmission (23) and individually attributed toilets have been associated with the control of VRE outbreaks (46, 47). Transmission via toilet seats was, however, never formally investigated. Our results strongly support the presumable transmission of pathogens through a shared toilet seat.

Because we found a relevant concentration of SPED on a doctor's mobile phone far from the study patients' room and because mobile devices are increasingly used at the bedside, we decided to design a quasi-realistic patient care scenario that guaranteed SPED could only reach the second patient through the mobile phone. The different contamination levels found on the phone's screen and back, again indicate the translation of hand touching into SPED detection patterns. Of note, the well-known risk of pathogen transmission through stethoscopes was echoed in this experiment by a higher SPED load. Thakur et al. (27) equally found stethoscopes to transmit a surrogate marker and MRSA. Thus, we agree with other authors who have suggested targeted cleaning of stethoscopes (48, 49) and phones (50-52) before.

This study has limitations. First, the number of conducted experiments did not allow to perform comparative statistics. Our goal was to use SPED for the first time in a real-life hospital setting and outbreak situation and to test if toilet seats need indeed to be considered in the spread of VRE or other potentially multi-drug resistant enteric flora. Second, as is the case with other surrogate tracers (27), habitual disinfection products do not inactivate SPED, while thorough cleaning with detergent and water does. This precludes mimicking real-life transmission perfectly, but instead allows to trace potential transmission pathways in the absence of disinfection procedures or, as our patient experiment shows, with the flawed execution of cleaning and disinfection procedures as it is often observed in real life. Further development of the SPED technology rendering the particles sensitive to disinfection agents might be feasible. Third, the extent of the spread of SPED ultimately depends on the quantity initially applied, but as Otter et al. (12) stated, the presence of pathogens at any concentration carries a risk for a transmission. Furthermore, the interpretation of relative quantity of recovered SPED must be taken with caution, since it depends on many factors including the swabbing technique. This does, however, not interfere with the discovery of transmission pathways. Fourth, by which intermediate transmission steps SPED reach the detection sites

(e.g., the doctor's keyboard or mobile phone) remains unknown. Therefore, time intervals and swabbing sites must be determined based on an initial hypothesis. Resolution can be increased by increasing the number of swabbing sites and rates as did Oelberg et al. (26), or by adding targeted evaluations as in our mobile device experiment.

Conclusion

In conclusion, SPED spread between patients through shared toilet use in a two-bed patient room, starting from a small, contaminated skin area in one patient. This finding highlighted the need for a reliable cleaning protocol, specifically as a potentially successful control element of an ongoing VRE outbreak. Intravenous pumps, mobile phones, and stethoscopes equally qualify as transmission hubs. And finally, the well-established transmission risk associated with patients' and HCWs' hands was confirmed. With this study, SPED were successfully applied in a real-life healthcare environment for the first time. Future development of the SPED tracer system could attempt to render SPED sensitive to common disinfection procedures and combine them with automated registration of human activity to increase natural fidelity.

List of abbreviations

aOR: adjusted odds ratio
HCAI: healthcare associated infections
HCW: healthcare worker
HCWH: healthcare worker's hands
HH: hand hygiene
mQ water: ultrapure MilliQ water (type 1, 18.2 M Ω ·cm at 24°C, Milli-Q®; Merck, Darmstadt, Germany)

297 MRSA: methicillin-resistant *Staphylococcus aureus*
298 qPCR: quantitative polymerase-chain-reaction
299 SPED: silica particles with encapsulated DNA
300 VRE: vancomycin-resistant enterococci

301 **Declarations**

302 **Ethics approval and consent to participate**

303 The Ethics Board of the Canton of Zurich reviewed the study protocol and formally
304 waved the necessity for a full ethics review based on the Swiss Law on Research on Humans
305 [BASEC-Nr. Req-2020-00974].

306

307 **Consent for publication**

308 Not applicable

309

310 **Availability of data and materials**

311 The datasets analysed during the current study are available from the corresponding author on
312 reasonable request.

313

314 **Competing interests**

315 RNG declares a financial interest as a shareholder of Haelixa AG, Kempthal,
316 Switzerland. IP on DNA encapsulated into silica nanoparticles is licensed to Haelixa AG. All
317 other authors have no conflicts of interest. HS reports a travel grant and speaker's honorary
318 from AstraZeneca in 2020 and speaker honorary from agfam (non-profit) and Livinguard AG
319 in 2021 not related to this work.

320

321 **Funding**

The study did not receive dedicated funding.

Authors' contributions

CU, HS, RNG and AML conceptualized and designed the study. JK synthesized the SPED and took an advisory role in planning the field experiments and in improving the sampling technique. AML and CU took explorative experiments in the lab, planned the field experiments, and conducted in-lab-preparations before all field experiments. CU conducted all field experiments. CU and AML analysed all samples in the laboratory gaining raw data. AML performed particle characterization, optimized the qPCR protocol, and acquired the calibration curves. CU processed the raw data. CU, AML and HS evaluated the data. CU and AML drafted and finalised the manuscript; AML supplemented the technical aspects. HS and RNG took an advisory role during manuscript revision. All authors read and approved the final manuscript.

Acknowledgments

We would like to warmly thank all volunteers, patients, nurses, and physicians who participated in this study. We also want to express our special gratitude to Manuela Scotoni for her advice, and to Sarah York who proofread our manuscript as native English speaker.

References

1. WHO. Report on the Endemic Burden of Healthcare-Associated Infection Worldwide. Geneva, Switzerland: World Health Organization; 2011.
2. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. 2009.
3. O'Neill J. Antimicrobial resistance antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014.

- 348 4. Buetti N, Wassilew N, Rion V, Senn L, Gardiol C, Widmer A, et al. Emergence of
349 vancomycin-resistant enterococci in Switzerland: a nation-wide survey. *Antimicrob Resist*
350 *Infect Control*. 2019;8:16.
- 351 5. Thierfelder C, Keller PM, Kocher C, Gaudenz R, Hombach M, Bloemberg GV, et al.
352 Vancomycin-resistant *Enterococcus*. *Swiss Med Wkly*. 2012;142:w13540.
- 353 6. Widmer AF. Vancomycin-resistant enterococci: an ongoing challenge for infection
354 control. *Swiss Med Wkly*. 2012;142:w13554.
- 355 7. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, et al.
356 Evidence-based model for hand transmission during patient care and the role of improved
357 practices. *Lancet Infect Dis*. 2006;6(10):641-52.
- 358 8. Sax H, Allegranzi B, Uçkay I, Larson E, Boyce J, Pittet D. 'My five moments for hand
359 hygiene': a user-centred design approach to understand, train, monitor and report hand
360 hygiene. *J Hosp Infect*. 2007;67(1):9-21.
- 361 9. Gould DJ, Moralejo D, Drey N, Chudleigh JH. Interventions to improve hand hygiene
362 compliance in patient care. *Cochrane Database Syst Rev*. 2010(9):Cd005186.
- 363 10. Clack L, Scotoni M, Wolfensberger A, Sax H. "First-person view" of pathogen
364 transmission and hand hygiene - use of a new head-mounted video capture and coding tool.
365 *Antimicrob Resist Infect Control*. 2017;6:108.
- 366 11. Otter JA, Yezli S, Salkeld JA, French GL. Evidence that contaminated surfaces
367 contribute to the transmission of hospital pathogens and an overview of strategies to address
368 contaminated surfaces in hospital settings. *Am J Infect Control*. 2013;41(5 Suppl):S6-11.
- 369 12. Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the
370 transmission of nosocomial pathogens. *Infect Control Hosp Epidemiol*. 2011;32(7):687-99.
- 371 13. Wolfensberger A, Clack L, Kuster SP, Passerini S, Mody L, Chopra V, et al. Transfer
372 of pathogens to and from patients, healthcare providers, and medical devices during care

373 activity-a systematic review and meta-analysis. *Infect Control Hosp Epidemiol*.
374 2018;39(9):1093-107.

375 14. Ray AJ, Hoyer CK, Taub TF, Eckstein EC, Donskey CJ. Nosocomial transmission of
376 vancomycin-resistant enterococci from surfaces. *JAMA*. 2002;287(11):1400-1.

377 15. Drees M, Snyderman DR, Schmid CH, Barefoot L, Hansjosten K, Vue PM, et al. Prior
378 environmental contamination increases the risk of acquisition of vancomycin-resistant
379 enterococci. *Clin Infect Dis*. 2008;46(5):678-85.

380 16. Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior
381 room occupants. *Arch Intern Med*. 2006;166(18):1945-51.

382 17. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in
383 healthcare-associated infections. *Current Opinion in Infectious Diseases*. 2013;26(4).

384 18. Stiller A, Salm F, Bischoff P, Gastmeier P. Relationship between hospital ward design
385 and healthcare-associated infection rates: a systematic review and meta-analysis. *Antimicrob*
386 *Resist Infect Control*. 2016;5:51.

387 19. McDonald EG, Dendukuri N, Frenette C, Lee TC. Time-Series Analysis of Health
388 Care-Associated Infections in a New Hospital With All Private Rooms. *JAMA Intern Med*.
389 2019;179(11):2019. p. 1501-6.

390 20. Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of
391 vancomycin-resistant enterococci via health care worker hands. *Arch Intern Med*.
392 2005;165(3):302-7.

393 21. Hayden MK, Blom DW, Lyle EA, Moore CG, Weinstein RA. Risk of hand or glove
394 contamination after contact with patients colonized with vancomycin-resistant enterococcus
395 or the colonized patients' environment. *Infect Control Hosp Epidemiol*. 2008;29(2):149-54.

396 22. Randle J, Arthur A, Vaughan N. Twenty-four-hour observational study of hospital
397 hand hygiene compliance. *J Hosp Infect*. 2010;76(3):252-5.

- 398 23. Cassone M, Mantey J, Perri MB, Gibson K, Lansing B, McNamara S, et al.
399 Environmental Panels as a Proxy for Nursing Facility Patients With Methicillin-Resistant
400 *Staphylococcus aureus* and Vancomycin-Resistant *Enterococcus* Colonization. *Clin Infect*
401 *Dis.* 2018;67(6):861-8.
- 402 24. Giannini MA, Nance D, McCullers JA. Are toilet seats a vector for transmission of
403 methicillin-resistant *Staphylococcus aureus*? *Am J Infect Control.* 2009;37(6):505-6.
- 404 25. Scotoni M, Koch J, Julian TR, Clack L, Pitol AK, Wolfensberger A, et al. Silica
405 nanoparticles with encapsulated DNA (SPED) - a novel surrogate tracer for microbial
406 transmission in healthcare. *Antimicrob Resist Infect Control.* 2020;9(1):152.
- 407 26. Oelberg DG, Joyner SE, Jiang X, Laborde D, Islam MP, Pickering LK. Detection of
408 pathogen transmission in neonatal nurseries using DNA markers as surrogate indicators.
409 *Pediatrics.* 2000;105(2):311-5.
- 410 27. Thakur M, Alhmidi H, Cadnum JL, Jencson AL, Bingham J, Wilson BM, et al. Use of
411 viral DNA surrogate markers to study routes of transmission of healthcare-associated
412 pathogens. *Infect Control Hosp Epidemiol.* 2020:1-6.
- 413 28. Alhmidi H, Cadnum JL, Jencson AL, Gweder AA, Donskey CJ. Sharing is not always
414 a good thing: Use of a DNA marker to investigate the potential for ward-to-ward
415 dissemination of healthcare-associated pathogens. *Infect Control Hosp Epidemiol.*
416 2019;40(2):214-6.
- 417 29. Alhmidi H, John A, Mana TC, Koganti S, Cadnum JL, Shelton MB, et al. Evaluation
418 of Viral Surrogate Markers for Study of Pathogen Dissemination During Simulations of
419 Patient Care. *Open Forum Infect Dis.* 2017;4(3):ofx128.
- 420 30. John A, Alhmidi H, Cadnum JL, Jencson AL, Donskey CJ. Contaminated Portable
421 Equipment Is a Potential Vector for Dissemination of Pathogens in the Intensive Care Unit.
422 *Infect Control Hosp Epidemiol.* 2017;38(10):1247-9.

31. Alhmidi H, Koganti S, Cadnum JL, Jencson AL, John A, Donskey CJ. Dissemination of a nonpathogenic viral DNA surrogate marker from high-touch surfaces in rooms of long-term care facility residents. *Am J Infect Control*. 2017;45(10):1165-7.
32. Koganti S, Alhmidi H, Tomas ME, Cadnum JL, Jencson A, Donskey CJ. Evaluation of Hospital Floors as a Potential Source of Pathogen Dissemination Using a Nonpathogenic Virus as a Surrogate Marker. *Infect Control Hosp Epidemiol*. 2016;37(11):1374-7.
33. Tomas ME, Cadnum JL, Mana TS, Jencson AL, Koganti S, Alhmidi H, et al. Utility of a Novel Reflective Marker Visualized by Flash Photography for Assessment of Personnel Contamination During Removal of Personal Protective Equipment. *Infect Control Hosp Epidemiol*. 2016;37(6):711-3.
34. Alhmidi H, Li DF, Cadnum JL, Haq MF, Pinto-Herrera NC, Wilson BM, et al. Use of simulations to evaluate the effectiveness of barrier precautions to prevent patient-to-patient transfer of healthcare-associated pathogens. *Infection Control & Hospital Epidemiology*. 2020;1-6.
35. Alhmidi H, Koganti S, Tomas ME, Cadnum JL, Jencson A, Donskey CJ. A pilot study to assess use of fluorescent lotion in patient care simulations to illustrate pathogen dissemination and train personnel in correct use of personal protective equipment. *Antimicrob Resist Infect Control*. 2016;5:40.
36. Paunescu D, Puddu M, Soellner JO, Stoessel PR, Grass RN. Reversible DNA encapsulation in silica to produce ROS-resistant and heat-resistant synthetic DNA 'fossils'. *Nat Protoc*. 2013;8(12):2440-8.
37. Grass RN, Schälchli J, Paunescu D, Soellner JOB, Kaegi R, Stark WJ. Tracking Trace Amounts of Submicrometer Silica Particles in Wastewaters and Activated Sludge Using Silica-Encapsulated DNA Barcodes. *Environmental Science & Technology Letters*. 2014;1(12):484-9.

448 38. Bloch MS, Paunescu D, Stoessel PR, Mora CA, Stark WJ, Grass RN. Labeling milk
449 along its production chain with DNA encapsulated in silica. *J Agric Food Chem*.
450 2014;62(43):10615-20.

451 39. Mora CA, Paunescu D, Grass RN, Stark WJ. Silica particles with encapsulated DNA
452 as trophic tracers. *Mol Ecol Resour*. 2015;15(2):231-41.

453 40. Mikutis G, Deuber CA, Schmid L, Kittila A, Lobsiger N, Puddu M, et al. Silica-
454 Encapsulated DNA-Based Tracers for Aquifer Characterization. *Environ Sci Technol*.
455 2018;52(21):12142-52.

456 41. Croissant JG, Fatieiev Y, Khashab NM. Degradability and Clearance of Silicon,
457 Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles.
458 *Advanced Materials*. 2017;29(9):1604634.

459 42. Huslage K, Rutala WA, Sickbert-Bennett E, Weber DJ. A quantitative approach to
460 defining "high-touch" surfaces in hospitals. *Infect Control Hosp Epidemiol*. 2010;31(8):850-
461 3.

462 43. Drankiewicz D, Dundes L. Handwashing among female college students. *American*
463 *Journal of Infection Control*. 2003;31(2):67-71.

464 44. Shams AM, Rose LJ, Edwards JR, Cali S, Harris AD, Jacob JT, et al. Assessment of
465 the Overall and Multidrug-Resistant Organism Bioburden on Environmental Surfaces in
466 Healthcare Facilities. *Infect Control Hosp Epidemiol*. 2016;37(12):1426-32.

467 45. Eckstein BC, Adams DA, Eckstein EC, Rao A, Sethi AK, Yadavalli GK, et al.
468 Reduction of *Clostridium Difficile* and vancomycin-resistant *Enterococcus* contamination of
469 environmental surfaces after an intervention to improve cleaning methods. *BMC Infect Dis*.
470 2007;7:61.

471 46. Pearman JW. 2004 Lowbury Lecture: the Western Australian experience with
472 vancomycin-resistant enterococci - from disaster to ongoing control. *J Hosp Infect*. 63.
473 England2006. p. 14-26.

47. Vuichard-Gysin D, Schlegel, M. Troillet, N. Senn, L. Marschall, J. Blanc, D. S. Buetti, N. Egli, A., Kuster SK, A. Balmelli, C. Sommerstein, R. Narthey, L. Masserey Spicher, V. Gardiol, C., Widmer AF, Harbarth S. Eindämmung der Verbreitung von Vancomycin-resistenten Enterokokken (VRE) in der Schweiz: Aktualisierung der nationalen Empfehlungen. VRE task force, on behalf of Swissnoso; 2019.
48. Longtin Y, Schneider A, Tschopp C, Renzi G, Gayet-Ageron A, Schrenzel J, et al. Contamination of Stethoscopes and Physicians' Hands After a Physical Examination. Mayo Clinic Proceedings. 2014;89(3):291-9.
49. O'Flaherty N, Fenelon L. The stethoscope and healthcare-associated infection: a snake in the grass or innocent bystander? Journal of Hospital Infection. 2015;91(1):1-7.
50. Brady RRW, Wasson A, Stirling I, McAllister C, Damani NN. Is your phone bugged? The incidence of bacteria known to cause nosocomial infection on healthcare workers' mobile phones. Journal of Hospital Infection. 2006;62(1):123-5.
51. Simmonds R, Lee D, Hayhurst E. Mobile phones as fomites for potential pathogens in hospitals: microbiome analysis reveals hidden contaminants. Journal of Hospital Infection. 2020;104(2):207-13.
52. Martina PF, Martinez M, Centeno CK, Von Specht M, Ferreras J. Dangerous passengers: multidrug-resistant bacteria on hands and mobile phones. Journal of preventive medicine and hygiene. 2019;60(4):E293-E9.

Table 1. Swabbing sites in the ‘Patient experiment’ for all three runs

	Sampling sites before deployment of SPED at baseline	Sampling sites immediately after toilet sequence	Sampling sites after eight- hour interval
Patient skin			
Subgluteal skin patient A	X	X	
Hands/palms patient A	X		X
Subgluteal skin patient B	X	X	
Hands/palms patient B	X		X
Restroom			
Toilet seat after patient A	X	X	
Flush plate after patient A	X	X	
Tap handle after patient A	X	X	
Door handle after patient A	X	X	
Toilet seat after patient B	X	X	
Flush plate after patient B	X	X	
Tap handle after patient B	X	X	
Door handle after patient B	X	X	
Patient room			
Bed control patient A	X		X

	Sampling sites before deployment of SPED at baseline	Sampling sites immediately after toilet sequence	Sampling sites after eight- hour interval
Private phone patient A*	X		X
Entertainment device patient A†	X		X
Intravenous pump patient A	X		X
Bed control patient B	X		X
Private phone patient B*	X		X
Entertainment device patient B†	X		X
Intravenous pump patient B	X		X
Nurse's office			
Nurse's mobile phone	X		X
Nurse's office keyboard	X		X
Doctor's office			
Doctor's mobile phone	X		X
Doctor's office Keyboard	X		X

495

496 **Legend:** SPED, silica nanoparticles with encapsulated DNA

497 * The patients' private mobile phone was swapped if available, otherwise the beside phone
498 provided by hospital.

499 † The most used device was assessed (among tablet, e-reader, laptop, hospital bedside TV):
500 Run 1) A: tablet, B: bedside hospital TV; Run 2) A: e-reader, B: bedside hospital TV; Run 3)
501 A: tablet, B: bedside hospital TV

502 **Table 2. Swabbing sites in the ‘Mobile device experiment’ for both runs**

	Swabbing sites before deployment of SPED as baseline	Swabbing sites after patient care sequence
Patient A’		
Wrist, radial pulse point	X	X
Neck, carotid pulse point	X	X
Chest, Erb’s point	X	X
Doctor A		
Cheek, phone touching point	X	X
Hands, palms	X	X
Stethoscope A, chest piece	X	X
Patient B’		
Wrist, radial pulse point	X	X
Neck, carotid pulse point	X	X
Chest, Erb’s point	X	X
Doctor B		
Cheek, phone touching point	X	X
Hands, palms	X	X
Stethoscope B, chest piece	X	X
Mobile Phone		

	Swabbing sites before deployment of SPED as baseline	Swabbing sites after patient care sequence
Phone, frontside screen	X	X
Phone, backside	X	X

503

504 **Legend:** SPED, silica nanoparticles with encapsulated DNA

Figure 1. Floor plan of the ‘Patient experiment’ ward with room assignments

Legend: The floorplan shows the study ward three times (once for each study run) and the localisation of the two-bed patient room, shared restroom, nurses’ and doctor’s office in the study ward. In **Run-1** the doctor’s office was situated on another floor and does therefore not appear in the floor plan. The plus signs indicate rooms with one or more positive SPED swabbing results at 8-hour follow-up. Detailed swabbing sites s. **Table 1**. SPED, silica nanoparticles with encapsulated DNA.

513 **Figure 2. Setup of the ‘Mobile device experiment’**

514

515

516

517

518

519

520

521

Legend: Scenarios plot: 1) Researcher deploys SPED on neck (A. carotis), chest (Erb’s point), and wrist (A. radialis) of **Patient-A’**; 2) **Doctor-A** listens to heart sounds and takes radial pulse of **Patient-A’**; 3) Phone rings, **Doctor-A** takes the call for 30 seconds, then leaves the experiment scene; 4) Phone rings again, **Doctor-B** takes the call for 30 seconds; and 5) listens to heart sounds and takes radial pulse of **Patient-B’**. Star symbols indicate SPED swabbing sites.

SPED, silica nanoparticles with encapsulated DNA.

Figure 3. Results of the ‘Explorative experiments’

Legend: Explorative experiment 1: Transmission of SPED deployed to subgluteal human skin to inanimate objects such as the toilet seat or the door handle through a standardized toilet sequence; Explorative experiment 2: Transmission of SPED deployed on **Participant-A**’s subgluteal skin to **Participant-B**’s subgluteal region through successive use of the same toilet.

SPED, silica nanoparticles with encapsulated DNA.

530 **Figure 4. Results of the ‘Patient experiment’ (Run-1 to Run-3)**

531 **Legend:** SPED, silica nanoparticles with encapsulated DNA.

532

533
534 **Figure 5. Results of the ‘Mobile device experiment’**

535
536 **Legend:** [NIL]

537 **Appendix**

538 **Technical Appendix**

539 *DNA barcode sequences*

540 DNA barcodes were ordered as single strands at a length of 65 nucleotides, with 40%
541 GC-content, as listed in Appendix Table 1. The sequences were synthesized by Microsynth
542 AG (Balgach, Switzerland) and shipped in dried state. Previous to annealing, the single
543 strands were dissolved in annealing buffer (Tris 10 mmol/L pH 7.5-8.0, EDTA 1 mmol/L,
544 NaCl 50 mmol/L) to a final concentration of 5 g/L. For annealing, the single strands were
545 mixed together in equal parts, treated at 95 °C for 5 min and slowly cooled down to room
546 temperature.

547 *SPED synthesis*

548 Per batch of DNA encapsulation, 4 x 4 mL of silica nanoparticles (110 nm, 50 mg/mL
549 in isopropanol; Pinfire, Frankfurt a. M., Germany) were surface-functionalized in 4 falcon
550 tubes. For functionalization, 40 µg of N-trimethoxysilylpropyl-N,N,N- trimethylammonium
551 chloride (TMAPS) (50% wt in methanol; abcr, Karlsruhe, Germany) were added, followed by
552 12 hours of shaking at room temperature, at 900 rotations per minute (rpm). Next, a 2 mL
553 batch of 150 ng/µL of corresponding annealed DNA (sequences see Appendix Table 1) was
554 added to 200 mL ultrapure water (mQ; type 1, 18.2 MΩ·cm at 24°C, Milli-Q®; Merck,
555 Darmstadt, Germany), followed by adding 0.4 g of the functionalized particles and vortexing
556 for 10 seconds. Subsequently, 4 µL TMAPS were added, before vortexing and sonicating for
557 20 seconds. Then, 62.5 µL of tetraethyl orthosilicate (TEOS) (≥99.0%; Sigma-Aldrich, St.
558 Louis, Missouri, USA) were added. The mixture was shaken for 5 h at 600 rpm. In a further
559 step, 10 mL iPrOH and 5.9 mL TEOS were mixed with 484.1 mL ultrapure water and

combined with the previous suspension. The batch was then stirred for 4 days at 600 rpm.

Three different batches were synthesized, each labeled with its own DNA barcode.

SPED characterization

DNA loading of the SPED batches was estimated by measurement of DNA concentration in solution before and after the reaction on a photometer (NanoDrop 2000c; Thermo Fisher Scientific, Waltham, Massachusetts, US), the difference being the amount of loaded DNA.

Hydrodynamic size distributions of SPED in suspension (~2 mg/mL in mQ water) were measured using a dispersion analyser (LUMiSizer, 470 nm light source; LUM GmbH, Berlin, Germany). Transmission profiles were recorded in time intervals of 5 seconds, at a rotational speed of 3000-4000 rpm, for 2 h. Statistical data analysis was performed by SEPView® software provided with the dispersion analyser. For scanning electron microscopy (SEM), SPED were prepared at a concentration of 0.1 mg/mL in iPrOH, loaded on a STEM C-grid and dried under infrared light. Imaging was performed on a NovaNanoSEM450 device (Field Electron and Ion Company, Hillsboro, Oregon, US) at a voltage of 20 kV.

Recovery and processing of SPED

In our experiments SPED were diluted in ultrapure MilliQ water (type 1, 18.2 MΩ·cm at 24°C, Milli-Q®; Merck, Darmstadt, Germany) to a working concentration of 1 mg/mL, of which 3 mL were used for patient colonization. To detect SPED on skin or surfaces, a similar swabbing technique as established by Scotoni et al. (25) was applied. The swabbing technique included cotton swabs (Naturaline Wattestäbchen, Steinfels Swiss, Winterthur, Switzerland) premoistened in 20% glycerol solution (99+% Glycerol 1 L, VWR chemicals bvba, Leuven, Belgium; 20vol% in mQ water) that were rolled three times over a pre-defined area and then added to 2 mL microcentrifugation tubes (Eppendorf AG, Hamburg, Germany) pre-filled with 200 µL mQ water and stored at room temperature. To fit the cotton swabs in the tubes, swabs

were shortened with scissors. All samples were transported to the laboratory for further processing.

Quantification of SPED

The swabs obtained at the experimental site were stored at room temperature for a maximal duration of 14 hours before being processed. For subsequent SPED quantification, each sample was ultrasonicated for 15 min and briefly spun down in a minicentrifuge to clear the SPED from the cotton swab as much as possible. For the etching process 2 vol% of buffered oxide etch, consisting of 0.03 wt% ammonium hydrogen difluoride (NH₄FHF, pure; Merck, Darmstadt, USA) and 0.02 wt% ammonium fluoride (NH₄F, puriss.; Sigma-Aldrich, St. Louis, Missouri, USA), was added to the sample liquid to release the DNA from the silica particles. All samples were ultrasonicated again for 15 min after adding BOE.

The suspension was then analyzed by real-time quantitative PCR (LightCycler® 96, Roche Molecular Systems, Pleasanton, USA) with SYBR® Green Master Mix (KAPA SYBR FAST qPCR master mix universal (2x, Kapa Biosystems, cat. no. KK4601)). The qPCR total reaction volume was 20 µl made up of 5 µl sample solution, 1 µl each of 10 µM forward and reverse primer stock solutions (Microsynth AG, Balgach, Switzerland, Appendix Table 2), 10 µl mastermix, and 3 µl mQ water. The qPCR program contained a preincubation for 240s at 95 °C, followed by 40 cycles of a 3-step amplification protocol (2 s at 95 °C, 12 s at 60 °C, 4s at 72 °C). Technical triplicates were measured for each sample, using no-template controls as PCR negatives. Further calculations were based on qPCR cycle values (C_q value) provided by LightCycler96 Software standard protocol.

Calculation of SPED concentration per sample

To quantify the amount of SPED in each sample, calibration curves were measured. For each batch of SPED used in our experiments a dilution series with 5 to 6 different

concentrations (10^{-3} , 10^{-4} mg/mL, etc.) was measured to assign established particle concentrations to the according cycle value from the qPCR.

The qPCR cycle values of the dilution series were plotted against the logarithmic particle concentration (in mg/mL resulting in a calibration curve. Use of linear regression of the single log chart generates a curve in the form of $y = ax + b$ (y as the cycle value and x as the ln of the concentration), consequently the concentration equals $e^{y/m-b}$.

The concentration of a given sample was calculated using the above formula with the respective regression parameters (Appendix Table 3). Error bars are based on the standard deviation of technical triplicates in qPCR data.

Evaluation of SPED and threshold

Prior to each experiment every sampling site was swabbed as a blank sample. The blank sample with the lowest qPCR cycle value and thus, the highest load of SPED was used as threshold for the according experiment. The cut-off value was calculated based on the qPCR cycle value plus the standard deviation of the technical triplicates. Sample concentration above threshold were considered as *positive* for SPED, values below as *negative*.

Scanning electron microscopy SEM

SPED were prepared as a suspension of 0.1 mg/mL in 2-propanol, loaded on a STEM C-grid and dried under infrared light. The samples were imaged on a NovaNanoSEM450 device (Field Electron and Ion Company, Hillsboro, Oregon, US) at a voltage of 20 kV at 52480x magnification (**Appendix Figure 1**).

629 **Appendix Table 1. DNA sequences used for SPED synthesis**

Name	Sequence
SPED-1 forward	TTATGGGCTCTAAGGATCTCTTCGTTGTCGTTAGGTTTCCTGCGTTTTTCGA TTCGAGGGTGAGTT
SPED-1 reverse	AACTCACCTCGAATCGAAAAACGCAGGAACCTAACGACAACGAAGAGA TCCTTAGAGCCCATAA
SPED-2 forward	TATGCGCCTTTATACTCTTATAGGTATCCTGTTGCTGGCACTTTTTTCTAG CAAAGTCTTCTCCT
SPED-2 reverse	AGGAGAAGACTTTGCTAGAAAAAAGTGCCAGCAACAGGATACCTATAAG AGTATAAAGGCGCATA
SPED-3 forward	TAGCTCGTTCATAGAATCACTTCGCCGTACTCAACGTAGTGGTTTTTGTTT AGCTCAAACAGGTT
SPED-3 reverse	AACCTGTTTGAGCTAAACAAAAACCACTACGTTGAGTACGGCGAAGTGA TTCTATGAACGAGCTA

630

631

632 **Appendix Table 2.** Primer (forward and reverse) for each batch of SPED for qPCR

GM-06-S1 (SPED-1)	primer forward ATGGGCTCTAAGGATCTC primer reverse CTCACCCTCGAATCGAA
GM-06-S2 (SPED-2)	primer forward ATGCGCCTTTATACTCTTA primer reverse GGAGAAGACTTTGCTAGAA
GM-06-S3 (SPED-3)	primer forward AGCTCGTTCATAGAATCAC primer reverse ACCTGTTTGAGCTAAACAA

633

634

635 **Appendix Table 3.** Regression parameters for calculation of SPED concentration with the
 636 formula: $y = ax + b$ (y as the cycle value and x as the ln of the concentration)

Batch	a	b	R ² (coefficient of determination)
SPED-1 (GM-06-S1)	-1.404	-4.429	0.994
SPED-2 (GM-06-S2)	-1.645	-5.397	0.999
SPED-3 (GM-06-S3)	-1.852	-6.345	0.999

637

638

639 **Appendix Figure 1. Scanning electron microscopy image of dried SPED**

640

641 **Legend:** Scale bar indicates 500 nm.